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Transparency in decision modelling is an evolving concept. Recently, discussion has 
moved from reporting standards to open source implementation of decision analytic 
models. However, in the debate about the supposed advantages and disadvantages of 
greater transparency, there is a lack of definition. The purpose of this article is not to 
present a case for or against transparency, but rather to provide a more nuanced 
understanding of what transparency means in the context of decision modelling and how 
it could be addressed. To this end, we review and summarise the discourse to date, 
drawing on our collective experience. We outline a taxonomy of the different 
manifestations of transparency, including reporting standards, reference models, 
collaboration, model registration, peer review, and open source modelling. Further, we 
map out the role and incentives for the various stakeholders, including industry, 
research organisations, publishers, and decision-makers. We outline the anticipated 
advantages and disadvantages of greater transparency with respect to each 
manifestation, as well as the perceived barriers and facilitators to greater transparency. 
These are considered with respect to the different stakeholders and with reference to 
issues including intellectual property, legality, standards, quality assurance, code 
integrity, health technology assessment processes, incentives, funding, software, access 
and deployment options, data protection, and stakeholder engagement. For each 
manifestation of transparency, we discuss the ‘what’, ‘why’, ‘who’, and ‘how’. 
Specifically, their meaning, why the community might (or might not) wish to embrace 
them, whose engagement as stakeholders is required, and how relevant objectives might 
be realised. We identify current initiatives aimed to improve transparency to exemplify 
efforts in current practice and for the future. 
 
KEY POINTS FOR DECISION-MAKERS 
 There is a variety of manifestations of transparency in decision modelling, ranging 
in the amount of information and accessibility of information that they tend to 
provide. 
 There is a broad array of stakeholders who create, manage, influence, evaluate, 
use, or are otherwise affected by, decision models.  
 Given the range of stakeholders and interests related to increased transparency 
of decision models, achieving the benefits while managing the risks requires 
careful consideration. Issues such as intellectual property, legal matters, funding, 
use, and sharing of software need to be addressed.  





Transparency is a defining characteristic of all scientific endeavours. Without it, the 
integrity and validity of research findings cannot be independently tested and verified, 
which is necessary to ensure the reliable use of evidence in decision making. 
Daniels and Sabin [1] have argued that transparency is critical for a public agency “to be 
accepted as [a] legitimate moral authority for distributing health care fairly” [2]. Bodies 
such as the National Institute for Health and Care Excellence (NICE) in England and the 
Canadian Agency for Drugs and Technologies in Health (CADTH) require formal decision 
analysis as part of health technology assessment (HTA) submissions, which inform their 
recommendations for the adoption of health technologies. Thus, if we accept the 
arguments of Daniels and Sabin, models used to inform public decision-making ought to 
be transparent. 
Having established the principle that transparency is desirable, we take an instrumental 
approach in this paper to consider how transparency might effectively be achieved 
through different mechanisms including the use of reporting standards, open source 
models, model registration, and peer review. For each, we consider how they can best 
be employed to promote transparency and the degree to which they can deliver benefits. 
We consider how these different mechanisms interact with the objective functions of 
various agents involved in the development and use of models, such as analysts (both 
for-profit and non-profit), decision-makers, and academics. 
There are numerous potential benefits to greater transparency. Transparency can 
facilitate replication and reduce the prevalence of technical errors, leading to more 
reliable information being available to decision-makers. More effective sharing of 
information and model concepts could aid incremental improvements in model structure, 
improving external validity. Together, these factors should improve the credibility of 
models, leading to them being more influential in decision-making. In turn, this should 
lead to better-informed decisions regarding resource allocation to existing technologies, 
more appropriate access and pricing of newly introduced technologies, and more 
appropriate price signals to developers and investors. 
It is for these reasons that numerous attempts to identify good practices in decision 
modelling have incorporated transparency to a greater or lesser extent [3,4]. While 
there has been discussion in the literature about the benefits of greater transparency, 
the potential disadvantages and unintended consequences are poorly described. It is 
essential that all stakeholders understand the implications of greater transparency (in its 
various forms) in order to mitigate any risks and ensure that the benefits outweigh the 
costs. 
Yet, recommendations for achieving transparency in HTA and academic publications have 
been vague. Models are routinely reported in a way that does not facilitate interrogation 
or replication. Part of the problem, we believe, is that the concept of transparency in the 
context of decision modelling has not been adequately explored. There are a variety of 
ways in which research can be transparent, and any given piece of research may be 
simultaneously transparent and unclear in different respects. Furthermore, transparency 
is an evolving concept that needs to be revised as new practices develop. 
In this article, we provide a detailed consideration of transparency. We outline the 
various manifestations of transparency that have been demonstrated or hypothesised in 
the literature (‘what’). Based on this taxonomy, we reflect on the associated benefits and 




risks (‘why’) and explore the role of different stakeholders (‘who’). Finally, we consider 
the means by which effective transparency in the context of decision modelling might be 
achieved and the research that could guide this transition (‘how’). 
2. WHAT? MANIFESTATIONS OF TRANSPARENCY 
The International Society for Pharmacoeconomics and Outcomes Research and Society 
for Medical Decision Making (ISPOR-SMDM) Modelling Good Research Practices Task 
Force characterised transparency as “clearly describing the model structure, equations, 
parameter values, and assumptions to enable interested parties to understand the 
model” [3]. This definition allows for endless interpretations. What constitutes a clear 
description? What duty of ‘enablement’ rests with the modeller? Who should qualify as 
an interested party? And, importantly, what constitutes understanding? It is inevitable 
that the satisfaction of these requirements is subjective, and also that the achievement 
of transparency cannot be demonstrated in any consistent manner. Alternative 
definitions of transparency could extend beyond this definition, requiring replicability, for 
example. 
In this section, we do not seek to define transparency or to support or refute previous 
definitions. Rather, we assert that there is a variety of manifestations of transparency, 
which could satisfy the ISPOR-SMDM Task Force definition in diverse ways and to 
varying degrees. These manifestations vary in respect to which aspects of the modelling 
process are transparent and to whom. 
Figure 1 specifies the manifestations of transparency that we discuss in this paper, 
recognising that these are not mutually exclusive. Transparency can be increased (or 
decreased) along two dimensions. First, research reporting is more transparent if it 
provides a greater amount of information relating to the research, which we characterise 
as ‘depth’. Second, research is more transparent if the information provided is accessible 
to a greater number of people, which we characterise as ‘breadth’. Each manifestation 
may increase transparency along one or both of these dimensions and to varying 
extents. For example, each manifestation could be highly accessible or highly restrictive. 
There may be an inherent trade-off between completeness (depth) and accessibility 
(breadth), because ensuring the clarity and accessibility of information may become 
more challenging as the amount of information shared is increased. Nevertheless, the 
positioning of the items in Figure 1 is illustrative. We observe that no single 
manifestation of transparency is sufficient to achieve complete transparency. 
 





Figure 1: Manifestations of transparency 
Note: the positioning of the manifestations is illustrative and not a generalisable ranking 
of the expected impact of any manifestation of transparency in the context of a given 
model. 
 
2.1. Model registration 
Analysts and decision-makers do not routinely know about modelling studies that are 
currently planned or underway. Nor do they know about modelling studies that have 
been conducted but not reported. Thus, there is a lack of transparency in the process 
and wider ecosystem of modelling. 
Sampson and Wrightson proposed the creation of a generic model registry with a linked 
database of decision models [5]. Such a registry would be analogous to clinical trial 
registries and would serve some of the same purposes. In particular, it could help to 
reduce publication bias, which may be common in cost-effectiveness modelling [6,7]. 
The inclusion of a model in a registry would involve the sharing of a small amount of 
information with a wide audience. Of all the forms of transparency discussed in this 
article, a model registry would provide the least amount of information. The impact of 
such a registry would depend on the information recorded therein. Nevertheless, the 












Greater completeness of information 




the future, is a form of transparency that could create value. A model registry could 
extend transparency and encourage collaboration by complementing other initiatives and 
by recording the history of the development and application of a model. Disease-specific 
registries and databases have been created in diabetes [8] and cancer [9], and generic 
databases are also in development [10]. 
2.2. Reporting standards 
Perhaps the most widely used and long-standing approach to achieving transparency has 
been the adoption of reporting guidelines and standards. The Consolidated Health 
Economic Evaluation Reporting Standards (CHEERS) is one of the best-known and 
regularly used reporting guidelines for economic evaluations [11]. Insofar as they 
support fuller and more consistent reporting, methodological standards can also facilitate 
transparency. Methodological standards exist for the specific context of decision 
modelling in health care, notably the Philips checklist [4] and the ISPOR-SMDM Modeling 
Good Research Practices guidelines [12]. 
Reporting standards, guidelines, and checklists are principally of value in facilitating 
transparency with respect to the ‘soft’ aspects of the model development process. They 
encourage transparency in describing the theoretical basis for the model structure and 
the rationale for all aspects of model development. Transparency in this respect can only 
be achieved by a full description in writing. Reporting standards can help to ensure that 
the overall purpose of a modelling study is clear. They can also ensure that interested 
parties understand any assumptions inherent in the design or execution of the model. In 
discussing transparency, Philips and colleagues [4] focus particularly on the importance 
of describing structural assumptions inherent in the model and the means by which data 
are identified and used.  
Providing a greater amount of information in order to achieve transparency creates a risk 
of obfuscation, as key details may be lost in fuller reporting. Clarity of communication is 
necessary to ensure transparency with respect to accessibility, which can be supported 
by the use of guidelines. Reporting standards can also guide visual representation of 
model structures and processes, which can increase transparency with respect to 
accessibility. 
No reporting guideline can be perfect for every study. For example, it has been 
suggested that CHEERS may be insufficient for the reporting of cost-benefit analyses 
[13]. Reporting guidelines can become quickly outdated and are not usually a sufficient 
basis for achieving transparent reporting. The CHEERS authors themselves 
acknowledged that economic evaluation methods are evolving over time and that 
CHEERS should be reviewed for updating after several years of use [14]. Moreover, even 
if a guideline is well-suited and used in the reporting of a study, there is always room for 
different interpretations and subjectivity in its application. Clear and complete 
communication of the intricacies of a complex model can be very difficult to achieve 
within the confines of a journal article, even with the use of extensive supplementary 
appendices. This limits the scope of reporting standards in facilitating complete and 
transparent reporting. 
2.3. Reference models 
In some cases, there may be disparate solutions to modelling disease pathways, which 
could be reconciled and applied in a generalised way to numerous decision problems. 
Models developed on this basis have been described as reference models or policy 




models [15]. A framework for the development of reference models has been proposed, 
which the authors suggest would enhance transparency [16]. 
Reference models are typically the results of dedicated efforts, with more resources 
available for better modelling of the natural history of the disease and more complete 
evidence synthesis. They have been proposed as a way to ensure consistency in the 
development of models that represent the natural history of specific diseases [17]. 
Reference or policy models have been created for a variety of conditions, including 
cardiovascular disease [18], AIDS [19], cancer [20], and population health [21], among 
others. These models can be used to describe clinical pathways overlaying natural 
history, which may be jurisdiction-specific but still generalisable. 
We consider the development of reference models as a step towards transparency 
because, by their nature, reference models separate the model building activity from 
specific applications. As such, they provide an opportunity for transparent reporting of 
model structure and validation steps, independent of the nuances of individual policy 
questions that may create barriers to transparency. Individual applications of reference 
models will have more space (within the confines of the standards of contemporary 
publications) to elaborate on the incremental approaches they have made for the 
particular question at hand, enabling greater completeness of reporting. Reference 
models can be made available through the sharing of code or web-based interfaces (e.g. 
[22]). 
2.4. Open source modelling 
A growing number of decision models are developed using statistical programming 
languages. In this case, the characteristics of a model’s structure and execution can be 
fully described within source code. Models can be made open source if this source code is 
made publicly available with a suitable licence that enables full interrogation and 
adaptation of the source code. Thus, open source models have the potential to provide 
any interested stakeholder with the necessary information to precisely replicate a 
modelling study. Whilst there are examples of open source models (e.g. [22–24]), they 
remain scarce. Several initiatives have begun to operate in this space, including the 
Open-Source Model Clearinghouse, hosted by Tufts Medical Center [25], and the Open-
Source Value Platform, hosted by the Innovation and Value Initiative [26].  
Open source modelling is a significant step towards complete transparency. However, it 
should not be seen as a panacea because information other than the source code is 
required to fully understand a model. For many models, provision of the code alone 
would not enable replication because the code depends on data. Some source code 
might require specialist software to run, meaning that, while the code can be read by an 
evaluator, the results cannot easily be replicated. 
To evaluate complex model code without detailed documentation can be a challenge. 
Therefore, while open source may allow for the disclosure of a large amount of 
information relating to the execution of a model, it is not sufficient for all interested 
parties to understand it. 
2.5. Peer review 
Peer review is often conducted under conditions of confidentiality. It therefore provides 
an opportunity for analysts to be wholly transparent with a selection of peers who have 
agreed to review the work in detail while protecting their intellectual property.  




Transparency and peer review have a bidirectional relationship, with each enhancing the 
other. On the one hand, a manuscript providing a clear and complete report of the study 
allows for a more meaningful peer review, whereas a reviewer cannot comment on a 
particular methodological aspect of a study if it is not clear what was done. On the other 
hand, peer review often leads to a more complete study report in the final published 
paper (e.g. if a reviewer requests that the authors clarify or elaborate on their methods). 
In practice, reviewers cannot typically review a model in detail, either due to lack of 
expertise or lack of time. This may limit the value of transparency in peer review. 
Authors are often blind to the identities of reviewers and sometimes vice versa, and 
readers of the final published paper are usually blind to the reviewer comments and 
revisions. As such, matters relating to model development during the peer review 
process are not widely accessible, limiting transparency in model development. 
Here, we consider peer review as currently practiced, as a manifestation of 
transparency. It is important to note that there is a lively discussion ongoing around the 
role of peer review and its future in scholarly communication. In future, peer review 
processes may be adapted and decoupled from other publication processes [27], which 
could facilitate the review of models separately from their application to specific decision 
problems or description in research papers. 
2.6. Collaboration 
Arnold and Ekins proposed multi-stakeholder collaboration across various sectors, which 
would involve greater transparency between members of the modelling community [28]. 
Decision models in many disease areas are necessarily complex, which can mean that 
peer reviewers are not adequately equipped to fully understand the work. A prime 
example is health economics models to simulate diabetes and its complications [29]. 
While models like the UK Prospective Diabetes Study Outcomes Model have been 
reported in a high level of detail to promote transparency and reproducibility [30], their 
complexity can mean that only a highly specialised audience is able to interrogate them.  
One way to extend transparency is through the development of networks of health 
economists that are working on a particular disease area. There are examples of 
collaborative initiatives in a variety of conditions, including diabetes (the Mount Hood 
meetings) [31], muscular dystrophy (Project HERCULES) [32], chronic obstructive 
pulmonary disease [33], and cancer [20]. One of the most well-established networks is 
the Mt Hood Diabetes Challenge, which involves most groups that have developed 
diabetes simulation models [34]. The Mt Hood network meets every two years to 
undertake a series of pre-defined simulations known as challenges. Such meetings 
provide an opportunity for groups to test and cross-validate their models against each 
other as well as validate them using real-world data. The Fifth Mt Hood Challenge 
involved eight modelling groups, who were given four challenges such as replicating the 
results of major diabetes trials including ADVANCE and ACCORD [35]. Model outcomes 
for each challenge were compared with the published findings of the respective trials. 
The discussion of such challenges promotes scrutiny of models by other groups and 
thereby promotes transparency. 
Collaboration is a limited form of transparency in that only a key group of collaborators 
have full access to materials. However, by establishing a small specialised group, it is 
more feasible to ensure complete transparency of content. 




3. WHY? BENEFITS AND RISKS 
The importance of evidence-based medicine for tangible improvements in quality and 
length of life over the last century and across jurisdictions is known, and illustrated by 
the ongoing work of the Cochrane Collaboration [36]. The merit of a similarly evidence-
based approach to the creation of HTA tools to inform decision-making has long been 
recognised [37]. There are many potential benefits to transparency that have been 
proposed by commentators [3,38]. 
Transparency in modelling is essential for truly evidence-based decision making, just as 
clinical trial standards and rules have become a requisite component of evidence-based 
medicine. In the remainder of this section, we specify different aspects of the 
multifaceted benefits and risks of transparency in modelling, though by no means claim 
to provide a complete account. 
We believe that the main potential benefits and risks of greater transparency are related 
to three broad areas, as shown in Figure 2: productivity, scope and rigour, and 
accountability. 
 
Figure 2: The benefits and risks of greater transparency 
 
3.1. Productivity 
Greater transparency in modelling could reduce waste that arises from the duplication of 
efforts. Full documentation of process has been characterised as a means of achieving 
efficiencies in model development [39]. Model registration and disease-specific 
collaborations could prevent separate groups of analysts from unnecessarily commencing 
equivalent modelling studies [5]. 
Models are often created for a single purpose and then languish in journal archives, 
health authority databases, or various proprietary settings. Rather than using or 
updating a pre-existing model, new models are often created for new medications or 
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new indications at considerable time and financial expense [28]. The availability of 
reference models could help to avoid this situation, thus freeing up analysts’ time. 
Similarly, existing models could be ‘reused’ or ‘recycled’ with different data. 
A transparently reported model has the potential to be reused or recycled to answer new 
questions, either by incorporating additional elements or simply revising a decision 
analysis once new data become available. A model in a similar disease area or related 
decision problem provides a valuable resource, saving time on decisions over the model 
structure and key data sources. The analyst is able to review the decisions taken by the 
previous author(s) and judge whether they are appropriate for their own analysis.  
Furthermore, they can review the literature searches for parameter values to determine 
whether they are fit for purpose or require modifying or updating. 
With greater transparency, models could be continually revised as new information 
becomes available. One example where this approach has been applied is for the 
Birmingham Rheumatoid Arthritis Model (BRAM), which has subsequently been extended 
by several groups [40]. To do so, however, these groups have been required to each 
first rebuild the original model, which incurs large costs before new work can be done. 
With greater information sharing between different stakeholders, transparency may also 
lead to a reduction in delays in the modelling process or in health technology 
assessment. This is especially likely in cases where de novo models are built as part of 
an appraisal process in lieu of being able to access existing models. 
However, the achievement of transparency could greatly increase the time required for 
model development, with no discernible benefit. For example, if an analyst is to publish 
their model open source, it is likely that more time will be dedicated to annotation and 
otherwise making the code understandable to other users. Yet, if the model is never 
replicated, validated, recycled, or otherwise made use of, this time is wasted. There is 
also a lack of specific guidance on best practice in sharing model files in a transparent 
and accessible way, meaning that time expended in facilitating transparency could be 
ineffective. 
Concurrent with a greater workload, ensuring transparency may delay the release of 
decision models. We might also expect there to be diminishing marginal returns to 
greater transparency, implying that ‘complete’ transparency could be a suboptimal 
strategy. There is little evidence available to inform this productivity trade-off, though 
the time demands of open source modelling have been documented [24]. 
3.2. Scope and rigour 
In addition to facilitating more efficiency in current practice, transparency could also 
extend the scope and rigour of cost-effectiveness modelling. In particular, the quality of 
decision models could be improved if greater transparency facilitates more 
comprehensive testing. Replication and validation are means of distinguishing ‘good’ 
models from those that are ‘bad’, due to the presence of errors, bias, or poor 
representation of the decision problem. 
Transparency in peer review can allow for a fuller assessment of the validity of the 
analysis ahead of publication, which may be especially valuable if it provides greater 
opportunity for refinement of models. This has been recognised with respect to the 
statistical code used for analyses published in medical journals (see, for example [41]) 
and economic journals (see, for example [42]). In the experience of one of the authors 
(TW), who is an editor of health economics journals that routinely request authors to 




provide a copy of their model for peer review, the practice helps confirm model validity, 
often results in model improvements, and sometimes identifies major errors.  
Improving the validity of models via increased transparency should lead to better 
decision making. This could result not only from having more accurate information from 
better models but also from decision-makers being more likely to use the evidence due 
to greater confidence in the models [43]. Greater transparency about the validity tests 
that have already been performed on a model can increase confidence in the accuracy of 
the model [44]. Greater transparency could also facilitate a meta-analytic approach to 
decision modelling, with meta-modelling representing a more robust source of evidence 
for decision making [45]. 
However, there is no guarantee that the replication, validation, or other reuse of models 
will lead to improvements in quality. If models are published open source, there is a risk 
that individuals may (intentionally or otherwise) misuse them. A fully transparent 
modelling infrastructure could allow for misuse to be identified but, without ubiquity in 
transparency, it creates a greater opportunity (or risk) for models to be taken ‘off-the-
shelf’ and applied inappropriately and with opacity. 
3.3. Accountability 
Registering models and reporting them fully could reduce publication bias and help to 
make plain any bias in the reporting or methods [46]. Transparency can increase 
accountability for both the analysts developing the models and the decision-makers 
using them.  
From an analyst’s perspective, greater accountability may be beneficial if models are 
explicitly reused with appropriate credit, rather than being an implicit influence. Reuse 
and reapplication of a model can signal the quality of an analyst’s work and bring career 
benefits. Where models are not transparently reported, but influence future modelling 
work, intellectual property cannot be easily identified. From a decision-maker's 
perspective, in line with the notion of accountability for reasonableness (the idea that 
decision-making processes with respect to the rationing of health care must be public 
[2]), greater transparency could enable decision-makers to more clearly justify their 
decisions. 
Greater transparency would facilitate the identification of errors in published work, 
which, while good for the development of the evidence base, could be damaging to 
analysts whose errors are identified. A system that mandates transparency could 
encourage analysts to be less transparent as a result of their concern about the potential 
for embarrassment or a negative career impact. 
It is not clear how accountability can or should be maintained after the transparent 
publication of a model. Once a model is in the public domain, it is not clear who should 
be responsible for the fidelity of the underlying model or any results derived from it. 
Analysts may (reasonably) deny responsibility for the results derived by others from a 
model that they have developed. 
4. WHO? STAKEHOLDERS 
To understand how and whether transparency should be extended in different respects, 
it is important to identify the motivations of different stakeholders and how they might 
be affected by transparency. There is a broad array of stakeholders in decision 
modelling. First, there are those who create, manage, and evaluate decision models. 




This includes industry, consultancies, research organisations, and HTA agencies. Second, 
there are stakeholders not directly involved in the development of models, but who are 
in a strong position to influence (and be affected by) the level of transparency in decision 
modelling. These include professional associations – for both individuals and 
organisations – and publishers. Third, there is wider society, which includes policymakers 
outside the health care resource allocation process and the public at large. Figure 3 
illustrates the role of these stakeholders and links between them, as described in the 
remainder of this section. We refer to appraisals in the broadest sense of evidence-based 
policymaking, which need not apply to HTA for drugs or devices. Each stakeholder’s 
influence can be summarised as operating on the supply-side, demand-side, or both. 
 
Figure 3: Stakeholders in decision modelling 
 
4.1. Industry 
Decision problems often arise as a result of new health technologies becoming available 
and decision-makers having to appraise their costs and benefits to inform 
reimbursement. In this context, decision models are routinely employed. Many HTA 
gatekeeper bodies require technology owners to submit the evidence for their 
reimbursement-seeking technologies, including NICE in England through their Single 
Technology Appraisal process. Many decision models are thus developed, sponsored, and 
owned by pharmaceutical companies and other manufacturers. 
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In an environment where the profit-maximising price of a patented health technology is 
partly or wholly determined by perceived payer-relevant value in terms of health 
outcomes in each jurisdiction, and profit-driven firms own the patents, these firms have 
an incentive to develop (or, as considered in 4.2, pay a consultancy to develop) and 
control models estimating the payer-relevant value of their patented technologies. To 
command a profit-maximising price across different jurisdictions in the current 
environment is, in many applications, to agree to a confidential discount to a list price 
with each payer who is not willing to meet the list price, with the aim of achieving the 
maximum price each payer is willing to pay. As such, pharmaceutical companies and 
agents therein may be incentivised to ensure confidentiality, rather than transparency. 
However, there may be countervailing drivers towards greater transparency. A more 
transparent model may be compelling for decision-makers. In addition, it is important to 
recognise that companies are not monolithic enterprises and the motives of individuals 
working in companies may act towards greater transparency [48]. 
4.2. Consultants 
Whilst pharmaceutical companies are responsible for models that are submitted to HTA 
bodies, the reality is that the majority are built by consultancies staffed with experts in 
modelling. Each consultancy will have different capabilities and views of appropriate 
methods. As the size of consultancies varies from departments in large publicly listed 
companies to privately held organisations with a handful of staff, it is also unlikely that a 
consensus view will be held amongst companies as to the appropriate level of 
transparency for modelling. 
The defining feature of modelling work conducted by consultancies is that it is done 
primarily to satisfy a client’s requirements. In this sense, consultancies might be 
considered rule-takers with respect to modelling standards and guidelines. Should 
guidelines mandate a level of transparency, it would effectively motivate companies to 
comply. 
Models to support HTA submissions are likely to be transparent for the parties involved, 
with the level of transparency being defined by the HTA agency (see section 4.5). 
Conversely, internal decision-making or pricing models, though built according to 
modelling standards, are likely to remain highly confidential with no documented 
evidence of their existence made available outside of the department for which they are 
developed. In this case, transparency may only extend to the client. 
Where models are used publicly, consultancies may want access to the code to be 
restricted to relevant stakeholders, and not made widely available. Even where HTA 
submission reports are provided in the public domain, model code is not published, and 
often model input data are redacted, which hampers replication. Whilst inefficient, this is 
driven by the desire for companies to keep their intellectual property secret and make it 
difficult for other companies to copy the elements which they see as key to their 
differentiation. 
Within the competitive bidding process to provide economic modelling services, there is 
currently little or no incentive for a profit-incentivised consultancy to include clauses for 
open source dissemination within proposals for work. To insert such a clause would 
typically lower the expected probability of the proposal bid being accepted, unless the 
industry procurement agent is incentivised by transparency. As described in 4.1, there is 
little to suggest this is likely to be the case. 




However, we should also recognise that revenue may be generated in different ways. For 
example, the development of a model may act as a ‘loss-leader’ with revenue being 
generated through add-on consultancy services. This may incentivise consultancies to 
develop open source models as a driver for subsequent consulting services. Likewise, as 
mentioned previously, if model transparency improves the likelihood that a model is 
viewed as unbiased, consultants and clients may support transparency.  
4.3. Researchers 
Universities, independent research organisations, and individual researchers all conduct 
decision modelling in the context of health care. It is important to note that there is not 
necessarily a clear distinction between research and consultancy, with some 
organisations (including university groups) conducting both with similar terms.  
Nevertheless, grant-funded or salaried researchers are likely to have the freedom to be 
rule-makers to a greater extent than consultants. In this respect, they may face different 
incentives regarding the use of the various manifestations of transparency. Researchers 
and research institutions may prioritise reputation over short-term profitability. The 
implications of this for transparency are ambiguous; researchers may benefit from 
greater publicity associated with transparency but may also fear the increased scope for 
criticism.  
As outlined in 3.3., greater accountability for model development may be associated with 
clearer identification of intellectual property, which could incentivise researchers to 
report models with greater transparency. However, the value of the intellectual property 
associated with the development of a model can extend beyond the immediate purposes 
of the model and its initial publication. Researchers may be able to derive further 
publications and credit from new applications or extension to a model that only they can 
fully implement. Thus, the incentives faced by researchers are likely to differ depending 
on the specifics of the work being conducted. 
There is considerable variation across academic organisations, especially looking 
internationally. There are examples of health economics researchers and teams working 
collaboratively with the health care system and driven primarily to ensure evidence and 
analysis-informed policy decision making. In such situations, open source and 
transparent modelling is likely to be embraced and nurtured, as exemplified by the work 
of Sadatsafavi and colleagues on the EPIC COPD reference model [22]. 
4.4. Publishers 
The dissemination of model reports is facilitated primarily via the publication of journal 
articles, and journals can have a positive influence on model transparency. For example, 
journals are often involved in the development and dissemination of research reporting 
standards, including those applicable to models, such as CHEERS. Being strong 
advocates for – and even enforcers of – reporting standards, journals have contributed 
to an improvement in reporting over time. Moreover, standard journal processes such as 
editorial assessment and peer review can routinely improve the completeness of a 
research report. Some journals have recognised the importance of transparency in 
achieving reproducible research and have created policies accordingly (see, for example 
[49]). 
In addition to improvements in the ‘depth’ of transparency via more comprehensive 
research articles, the open access movement has resulted in a marked increase in the 




‘breadth’ of transparency via wider access to articles when they are published with open 
access. 
4.5. Health care decision-makers 
HTA agencies, such as NICE and CADTH, are major beneficiaries and drivers of model 
transparency, and will likely be a major determinant of the fate of model transparency 
initiatives. HTA agencies play crucial roles in the approval of new health technologies for 
market entry in their respective jurisdictions. As part of submissions for approval of new 
health technologies, such agencies receive HTA reports, including economic evaluations 
and budget impact analyses, from the technology manufacturer, and embark on an 
internal or external assessment of the models. Transparency in the models will greatly 
enhance the capacity of such agencies towards evaluating the claims of cost-
effectiveness made by the manufacturer. 
Transparency in reporting and documentation can also enhance the value of one HTA 
agency’s work for other HTA agencies. The vast documentation made publicly available 
online for each NICE appraisal allows other agencies to learn from NICE’s own critique if 
subsequently appraising the same technology in the same indication, for different 
jurisdictions. For the most part, HTA agencies already enforce certain transparency 
standards, such as requiring the manufacturer to submit the model source code. 
Transparency in the HTA process should also be bidirectional. Agencies commission the 
development of models, and these models should be transparently shared with 
companies. 
In theory, it is already a requirement to base practice on a systematic review of the 
evidence. CADTH guidelines suggest that “Researchers should consider any existing well-
constructed and validated models that appropriately capture the clinical or care pathway 
for the condition of interest when conceptualizing their model.” Agencies could push the 
transparency agenda further by, for example, requiring the manufacturer to use 
reference models instead of their own in-house models. This should lead to the use (or 
improvement) of reference models. The European Network for Health Technology 
Assessment (EUnetHTA) is supporting a movement towards greater transparency in HTA 
submissions by providing a core HTA model framework and a guide to best practices 
[50,51].  
4.6. Professional associations 
Seeing potential benefits associated with transparency, a variety of organisations have 
articulated their support, including the International Society for Pharmacoeconomics and 
Outcomes Research (ISPOR), Health Technology Assessment International (HTAi), the 
Academy of Managed Care Pharmacy (AMCP) [52], and the Society for Medical Decision 
Making (SMDM). Professional associations for individuals involved in the development of 
decision models can facilitate collaboration within and between different stakeholder 
groups. Trade associations, such as the European Federation of Pharmaceutical 
Industries and Associations (EFPIA), might also play a role in enabling collaboration and 
providing infrastructure. 
It will be in the interest of professional associations to extend transparency if this 
reflects well on the profession or industry that they represent. For example, if 
transparency improves the legitimacy of modelling, the influence of relevant associations 
may be extended. Similarly, if transparency is seen to serve the public good, trade 
associations may be able to use it as a platform for positive publicity. 




4.7. Wider society 
A large part of the justification for the broader open science movement is that it serves 
society in a positive way. Especially when supported by public funding, research is often 
seen as a public good. Wider society can influence modelling practices through funders, 
policymakers, or via any other stakeholders, and could be affected by the level of 
transparency. 
Non-specialist audiences are unlikely to utilise information that provides greater 
transparency with respect to the depth of reporting. However, initiatives such as model 
registries could facilitate the work of patient groups and other stakeholders, who may 
wish to understand the nature of modelling work. This may be especially relevant to the 
allocation of research funding, which should be guided by the public’s priorities and by 
the prevailing research landscape. 
5. HOW? ACHIEVING TRANSPARENCY 
Having identified what transparency is, why we might want it, and who needs to be 
involved, we outline some of the areas in which changes need to be made in order to 
benefit from greater transparency. Given the range of stakeholders and interests related 
to increased transparency of decision models, achieving the benefits while managing the 
risks requires careful consideration. It is also worth considering that the achievement of 
transparency may be more or less difficult depending on the context and the nature of 
any given model. For example, there may be a trade-off between transparency and 
complexity, as more complex models consist of more information. We discuss three 
broad strategies that require attention: i) removing barriers, ii) creating incentives, and 
iii) establishing infrastructure. 
5.1. Removing barriers 
5.1.1. Legal 
Legal challenges can arise with respect to several manifestations of transparency. 
Collaboration may be particularly difficult for manufacturers, who are subject to antitrust 
legislation. This is an area where companies will need to tread carefully if they are to 
work together. In practice, it may mean working through a third party (such as a patient 
organisation or consultancy company) whereby such concerns are minimised because 
the project is hosted by the third party. Efforts should be focussed towards facilitating 
direct collaboration between companies on the development of an evidence base, 
without risk of legal proceedings. 
One example of collaboration which has managed to navigate this area is economic 
modelling in Duchenne Muscular Dystrophy. In this area, multiple companies developing 
assets have come together to jointly develop evidence that will be required for market 
access, including data on the natural history of the disease, burden of illness, and an 
economic model. Whilst there were numerous issues in the project being set up, the role 
of the patient organisation in holding the contracts and providing leadership was key 
[53]. 
The current flux in privacy law, particularly the introduction of the General Data 
Protection Regulation (GDPR) in the European Union, also complicates transparency in 
modelling. Analysts and agents need to be particularly careful regarding potentially 
identifiable patient data and how they are shared. This is an active area of research; how 




to anonymise data is particularly problematic in rare diseases, where even the most 
basic information needed for modelling potentially makes it possible to identify patients 
[54]. 
It is vital that model transparency initiatives are able to manage data protection 
requirements. The rise of open source statistical software such as R [55] and Python 
[56], and adoption of standard practices in structuring code, will increase accessibility 
and readability. Patient-level data can be replaced with either summary distributions or 
pseudo-patient level data (samples drawn from the respective joint summary 
distributions). 
5.1.2. Software 
Software plays an important role in the definition of model components and in 
stakeholders’ understanding of their function. Some modelling software is more suited to 
sharing and collaboration than others. Purpose-built software, such as TreeAge Pro, may 
have the benefit of allowing easy model development and use but can lack transparency. 
Microsoft Excel can be used to generate models that are transparent in the sense that 
the calculations are presented in the worksheets, and spreadsheet models are 
sometimes recommended on this basis [52]. However, for a reader to understand the 
model structure in more complex models, they may be required to trace the model 
calculations cell-by-cell. Thus, the choice of software can be a barrier to transparency or 
to the cost of deriving value from that transparency. Furthermore, the statistical 
limitations of Excel mean that often more sophisticated calculations are conducted in 
specialist statistical software such as Stata, which may be a further hindrance to 
transparency. 
5.1.3. Knowledge 
There are at least two respects in which analysts may not know how to effectively 
achieve transparency, due to a lack of knowledge. First, there is limited specific guidance 
on making decision models transparent. Second, many analysts (and those reviewing 
models) are not trained in the use of software that facilitates transparency. 
If reference models, open source modelling, or model registries are to be part of the 
model development process, then standards need to be developed to guide analysts in 
achieving best practice. The availability of guidance can help to create confidence in 
researchers to pursue transparency. Yet, selecting the best standards to use can also be 
challenging [57]. Wider uptake – and appropriate use – of standards, by both modellers 
and journals, should be encouraged, and research should evaluate the suitability of 
guidance relating to transparency. 
As outlined above, the use of particular software packages can hinder transparency. 
There is increasing use of script-based languages, such as R, to both generate statistical 
calculations for models and build models directly [58]. Such an approach can facilitate 
the sharing of models, either publicly as open source or within the context of peer review 
or collaboration. However, transparency depends on the code being well-structured and 
clearly commented and a user or reviewer is required to have knowledge of the language 
in order to validate, use, or adapt the model. There is a steep learning curve for analysts 
unfamiliar with script-based models (many of whom principally use Microsoft Excel), 
which can act as a barrier to transparency. There may also be barriers in the 
communication of models due to a lack of knowledge for end-users. However, this can 
be substantially mitigated with the use of open access interface packages, like the R 




package Shiny, which can be used to turn an R model into an interactive web application 
[59]. This allows a user without any R knowledge to use or, in part, validate the model. 
Research should identify why analysts use particular software packages and the 
implications of this for transparency. 
Training and education is key to addressing knowledge barriers, and should be directed 
towards the aforementioned challenges: knowledge of good practice and technical 
expertise. Further training opportunities need to be created to facilitate a transition to 
more transparent practices in the use of software. 
5.2. Creating incentives 
5.2.1. Monetary 
All stakeholders involved in the development of decision models are potentially 
motivated by financial incentives. If intellectual property rights are maintained when 
models are transparent, there is an opportunity to monetise models. Such an approach 
could potentially be adopted by consulting companies or researchers. Using script-based 
models, proprietary sections of code could be attributed to the developers and any 
updates vetted and versioned. In the research sector, policymakers could reward 
transparency with financial support. Such a scheme could be analogous (or contiguous) 
to existing national research assessments, such as the Research Excellence Framework 
in the UK. 
5.2.2. Non-monetary 
At present, analysts are, in general, not incentivised to ensure transparency in the 
development of models. In order to facilitate increases in transparency, a non-monetary 
incentive structure should be created. This may take the form of explicit sources where 
models can be cited (as has occurred with The Journal of Statistical Software) or forms 
of ‘kudos’ or credibility as seen on systems like GitHub [60]. Whilst incentives may help 
in promoting transparency, a change in culture to one where transparency is expected 
from all parties is more likely to have an effect than more ephemeral rewards, which 
may not apply equally across sectors (publications, for instance, are not a performance 
indicator in the commercial sector). 
5.2.3. Quality assurance 
Incentives to use (as well as create) transparent models should also be implemented. If 
more models are reported transparently, quality assurance will become increasingly 
important. Users of models are more likely to express demand for open source models or 
reference models if their quality is assured. This may involve testing of code integrity by 
a third party or other forms of validation. 
5.3. Establishing infrastructure 
5.3.1. Mandates 
As an alternative or complement to creating incentives, analysts could be mandated to 
make models transparent in specified ways. HTA agencies, in particular, are in a strong 
position to encourage transparency. For example, HTA agencies could tighten the 
requirements for confidentiality marking. Currently, HTA bodies provide guidance for 
companies to protect their confidential information but provide little incentive for 
companies to be as open as possible in doing so. Much of the documentation made 
available for each NICE technology appraisal – for example – contains redacted data. As 




noted in 4.5, HTA agencies could build on requirements for the manufacturer to base 
their model on a systematic review of evidence and submit the model source code, 
towards an open source model registry, noting confidentiality issues. 
As we see movement towards less emphasis on technology adoption and more 
discussion on ‘technology management’ by agencies and health care systems, the case is 
strengthened for ongoing maintenance of models, especially reference or policy models. 
The argument here is for policy models to be used as analytic infrastructure for health 
system management, with health economists supporting the search for efficiency 
(setting the agenda for policy changes) rather than reacting to a flow of technologies and 
guiding one-off yes/no decisions [61,62]. Further, technology management implies an 
ongoing assessment of technologies through their life-course, and models again 
represent the obvious analytic vehicle for this. If the health care system sees ongoing 
value in policy models then the funding for maintenance and development of such 
models could flow from the system itself. 
5.3.2. Platforms 
Bertagnolli and colleagues [63] have discussed data sharing for clinical trial results—a 
feat more than 60 years in the making—which has been hampered by similar forces to 
those facing the sharing of decision models, namely a lack of systems technology to 
facilitate the sharing of information. Some of the challenges can be overcome by using 
gatekeeper models (a central repository overseen by an independent expert committee), 
active open source data sharing models [63] and federated data models (whereby the 
data requester’s analyses are run from the data owner’s computer) [64]. 
There is an increasing number of online tools that are viable for storing and sharing 
model source code and related content, including GitHub, FigShare (Digital Science), and 
Mendeley (Elsevier). Code for models published in peer-reviewed journals can be 
provided as supplementary material and therefore available for further adaptation by 
other researchers. 
R models in particular lend themselves to being shared via a version-controlled code 
repository like GitHub. A repository can be archived and assigned a Digital Object 
Identifier, making it citable. All changes are tracked, which means the model can evolve 
beyond the initial publication and the differences between versions can be easily 
determined. This is particularly helpful for validation. Conflicts which may occur when 
collaborators are working on the same part of the code are flagged and can then be 
resolved to preserve code integrity. Anyone wishing to use the model can pull the code 
onto their own machine and amend accordingly. The effects of environment 
discrepancies can be averted by deploying via a software container platform such as 
Docker. The code and the dependencies required for it to run are packaged up together 
ensuring that model functionality and outcomes are the same on different machines. 
The information provided may not be an adequate basis on which to judge the 
appropriateness of the model, which will likely require an explanation. Several of us are 
involved in the development of an open source model exchange platform that would 
initially require manual model vetting via an advisory panel using the CHEERS checklist; 
this would eventually be replaced with an algorithm to automate the process [65]. 
Thus, there are many options already available (and more in development) that could 
constitute platforms for making models more transparent. Yet, the lack of an accepted 
platform and standards for easily sharing models means that very few are ever made 




available to peer reviewers, let alone expert readers, public health officials, or decision-
makers. A lack of knowledge in the use of existing platforms may be a barrier, and so 
training for decision modellers will be necessary. Concerns about intellectual property 
may also be a barrier to model transparency, for both individuals and organisations. 
Thus, it is important to create an infrastructure in which intellectual property is not 
threatened by initiatives to increase transparency. 
The infrastructure associated with maintaining any transparent modelling initiative will 
require funding. It is necessary that stakeholders should come together to identify who 
will sustainably fund the practical and technical support required. 
5.3.3. Stakeholder networks 
There are many stakeholders in the development and use of decision models in health 
care and an ongoing dialogue needs to be maintained. Analysts require reassurance that 
there are no serious risks associated with making models more transparent.  
Despite the importance of models for comparative effectiveness and cost-effectiveness 
research and guideline development, there is no efficient process for creating, 
disseminating, sharing, evaluating, and updating these models. These issues must be 
evaluated and debated in an open forum to facilitate collaboration while honestly 
exploring how best to afford protections where they are required or desired. Publishers 
may also play an intermediary role in the debate between different researchers, 
companies, and other stakeholders. Greater transparency can raise issues of copyright 
and access, so there is a need to define how model sharing can be achieved in a fair and 
equitable manner [3,28,66]. We have developed a special interest group (SIG) within 
ISPOR to curate an ongoing dialogue around the creation, dissemination, sharing, 
evaluation, and updating of open source cost-effectiveness models. 
There is a clear direction in health research internationally for a stronger patient 
orientation, with all research about patients being guided and driven by those with the 
lived experience of the illness in question (e.g. in Canada [67], the US [68], and the UK 
[69]). This case has been made in the specific context of decision modelling by van 
Voorn et al [70]. A key benefit of transparency, therefore, is that it potentially allows for 
the fuller engagement of patients and caregivers as stakeholders. Some groups are 
moving strongly in this direction, notably the Innovation and Value Initiative. 
6. CONCLUSION 
We have outlined six distinct (though connected) manifestations of transparency: i) 
model registration, ii) reporting standards, iii) reference models, iv) open source 
modelling, v) peer review, and vi) collaboration. Each of these involves different 
processes, promoting transparency in distinct ways. Any given initiative may involve the 
promotion or implementation of multiple manifestations of transparency, but it is 
important to recognise the unique role of each. This is because no single manifestation is 
a sufficient tool for the achievement of transparency, and each is subject to its own 
limitations, challenges, and benefits. Greater transparency in modelling has the potential 
to support wider and more effective scrutiny of models, which could lead to a reduction 
in technical errors and facilitate incremental improvements to support external validity. 
However, the implementation of transparency initiatives does not guarantee these goals 
and, in order to be successful, changes are required within the modelling community. 
Legal, practical, and intellectual barriers prevail, which could hamper transparency 




initiatives. It is vital that stakeholders work together to identify risks and opportunities in 
increasing transparency to develop a supportive and sustainable infrastructure. 
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